GenVec, Inc. uses differentiated, proprietary technologies to create superior therapeutics and vaccines. GenVec collaborates with leading companies and organizations, including Novartis, Merial, and the U.S. government, to support a portfolio of product programs that address significant human and animal health concerns. The company's development programs include therapeutic areas such as hearing loss, balance disorders, and cancer, as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV).
GenVec utilizes more than 20 Cornell technologies and methods involving gene therapy innovated by faculty members of Weill Cornell Medicine. The company's technologies are licensed from Cornell University.